General introductions by Dr Maarten van Dongen. International experts provide their up-to-date, specialist views on different topics followed by short interviews. Ample room for Q&A during the sessions.
Times indicated in Central European Summer Time (CEST).
|09:30||Introduction to Antimicrobial resistance (AMR)|
|A closer acquaintance to and demarcation of AMR. How AMR is viewed from different sectors and how we communicate about AMR: (how) is AMR adequately acknowledged.|
|10:00||Bacteria: desperately needed and detested
|What are bacteria, where do they occur and how do they spread. What types and subtypes are there and which ones are harmful or pathogenic. What function do bacteria have, what diseases in humans, animals and plants can they cause and why do we also desperately need bacteria.|
||Antibiotics: desperately needed but also cause of AMR
Expert: Dr Rohini Wadanamby; Lanka hospital, Colombo (Sri Lanka)
|What are antibiotics. How were they discovered and how do they work? What (classes of) antibiotics are there and how do they protect us? Why and when to use antibiotics and how to use appropriately and in a cost effective way. And when not to use..
|11:15||Antibiotic resistance & Antimicrobial resistance: the overall picture
|What are antibiotic resistance and AMR. How AMR develops and spreads around the world. Why AMR is increasingly threatening our health and food safety: statistics, socio-economic implications and consequences for public human and animal health.|
|12:00||Q&A and AMR cases|
|Reflection on the morning program, Q&A and AMR cases by participants.|
|13:15||The global strategy to combat AMR
|The WHO Global Action Plan and how National Action Plans add to the curbing AMR. How WHO, FAO and OIE join forces. What other organisations are involved and what role and (how) does the UN monitors. An overview of the global stakeholders.|
|13:45||6 Key strategies to tackle AMR in the One Health perspective|
|We explain the 6 important, key strategies in the One Health perspective. We show how the different strategies reinforce each other to ultimately lead to an effective, global control of AMR. What are the global challenges related to the individual strategies.
Includes Data Technologies to combat AMR & upcoming Policy Paper by Dr Leonid Chindelevitch; Imperial College London (UK)
||Strategy 1: Infection Prevention and Control and the key role of vaccination
Expert: Prof Cal MacLennan; Professor of Vaccine Immunology at the University of Birmingham (UK)
|Preventing infections results in the decreased use of antibiotics and prevents (resistant) bacteria from spreading. What is the impact of vaccination of humans and animals (as well as good sanitation, hygiene and use of disinfectants) to prevent AMR. The global bacterial vaccinology network BactiVac to accelerate the development of vaccines relevant to LMICs.|
||Strategy 2: Antibiotic Stewardship and challenges to apply worldwide
Expert: Anita E. Asamoah MPH; Public Health Epidemiologist/Researcher (Ghana)
|Monitoring and limiting the use of antibiotics reduces the risk of AMR. How this can be implemented in human and animal health care: feasibility in HIC and LMICs alike. How disturbing or needed are “illegal” illegal antibiotics sales.
Session includes introduction to the new, three step gamified program ‘Focus on Prescription’ by Derek van Dongen, Mindgame (NL)
||Strategy 3: Microbial Diagnostics and what new technologies may reach the market
Prof Till Bachmann; University of Edinburgh, Edinburgh (UK)
|Diagnostics help us to set the proper patient treatment. Diagnostics distinguish bacteria from viruses, identify bacterial species and determine the antibiotics sensitivity. Do we use diagnostics properly and do we use the proper diagnostics. What scientific developments are there and (when) will new diagnostic tools reach the market.|
||Strategy 4: Novel Antibiotics (in the context of a broken market)
Expert: Dr Lesley Ogilvie; Global AMR R&D Hub (Germany)
|New antibiotics, to which bacteria are still sensitive, are increasingly needed in the global fight against AMR. Why is this, and why do so limited numbers of new antibiotics appear on the market. What are the challenges and what role is played by CARB-X, GARDP, Global AMR R&D Hub, AMR Industry Alliance and AMR Action Fund and the IRAADD network.
Session includes a short presentation on the AMR Innovation Mission UK 2021 by Dr Phil Packer, Innovate UK (UK)
||Strategy 5: Alternative Antimicrobials such as phage therapy
Expert: Dr Chris Arts; Maastricht University Medical Centre and Eindhoven University of Technology (NL)
|Alternatives to antibiotics are increasingly important to curb AMR. In addition to phage therapy, antimicrobial tissue replacers, nanomaterials and probiotics appear to fight (resistant) bacteria without leading to AMR. What are the developments and what are the promises in theory and practice. Plus: the new DARTBAC research network.|
Strategy 6: Reducing Antibiotic Emissions in waste water
Antibiotics in effluents from hospitals and antibiotics producers, in surface (waste) water and in the environment lead to the emergence and spread of resistant bacteria. These can end up in the human food chain. What can we do about this and can we pay for this.
COVID-19: more AMR but less attention
Corona has unprecedentedly raised the global awareness that infectious diseases can have pandemic proportions. COVID-19 also impacts the use of antibiotics for the treatment of demonstrated (or not) secondary, bacterial infections.
Reflection on the afternoon program; Q&A and comments.